Insider Trading Update: La Jolla Pharmaceutical Company $LJPC

33217bfc40d0dab4185dec68a7b7439a

La Jolla Pharmaceutical Company (LJPC) insider have most recently took part in a trading activity. On Dec 27, 2017 Carver Jennifer, COO bought 1,000 shares having total worth of $33,220 at the price of $33.22 per share, following the transaction a total of 4,500 shares owned by Carver Jennifer. Before this latest buy, Carver Jennifer purchased LJPC at 1 other times during the past twelve months, for a total investment of $34,460 at an average of $34.46 per share.

Furthermore, over the past 12 months , the stock was traded 6 times by insiders. an employee of the company was the buyer in 6 instances.

Shares of La Jolla Pharmaceutical Company (LJPC) traded down 0.06% on Dec 28, 2017, hitting $32.45. 334,242 shares of the company’s stock traded hands. La Jolla Pharmaceutical Company has a 52 week low of $16 and a 52 week high of $38.44. The company’s market cap is $470 million.

La Jolla Pharmaceutical Company (LJPC) last announced its earnings results on Apr 27, 2017. The company reported -1.26 earnings per share (EPS) for the quarter, higher than the consensus estimate of -1.34 by $0.08., compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.96 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.

2017-04-27 2017-02-23 2016-02-25 2015-11-06 2015-08-07 2015-04-29 2015-03-16 2014-11-12 2014-08-14 2014-04-30
earnings per share -1.26 -1.44 -0.69 -0.70 -0.70 -0.59 -0.45 -0.37 -0.47 -0.93
Revenue(M) 0 0.09 0.41 0.65 0 0 0 0 0 0

La Jolla Pharmaceutical Co. was incorporated in 1989 in Delaware and reincorporated in California in 2012. The Company is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. Its drug development efforts are engaged in two product candidates: GCS-100 and LJPC-501. GCS-100 targets the galectin-3 protein, which, when overproduced by the human body, has been associated with chronic organ failure and cancer. In January 2013, the Company initiated a Phase 1/2 clinical trial with GCS-100 for the treatment of chronic kidney disease (CKD). LJPC-501 is a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome (HRS). the Company has a broad product portfolio consisting of both development-stage and discovery-stage products. In addition to GCS-100 and LJPC-501, the Company has several product candidates in the early development stage. These product candidates include LJPC-101, a subcutaneous formulation of GCS-100, LJPC-201, an oral galectin-3 inhibitor and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. It continuously evaluates opportunities to efficiently and effectively advance new product candidates into development for significant unmet medical needs. The Company faces competition from domestic and foreign biotechnology companies, large pharmaceutical companies and other institutions. The Company is subject to numerous government authorities in the United States and other countries.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.